Cited by Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients

Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients DOI

et al.

Korean Circulation Journal, Journal Year: 2024, Volume and Issue: 55(5), P. 426 - 426

Published: Dec. 9, 2024

Guidelines recommend target levels of low-density lipoprotein cholesterol (LDL-C) and intensive lipid-lowering therapy (LLT) in high-risk patients. However, the value escalating LLT when LDL-C targets are achieved with moderate-intensity statins is unknown. We aimed to evaluate benefits escalation this population. In retrospective propensity score-matched study, we screened data from two university hospitals between 2006 2021. Of 54,069 patients atherosclerotic cardiovascular disease (ASCVD), 3,205 who <70 mg/dL were included. After 1:3 matching, 1,315 (339 976 without) ultimately examined. The primary outcomes major adverse cerebrovascular events (MACCE)1 (cardiovascular death, nonfatal myocardial infarction, ischemic stroke) all-cause death. During a median follow-up 5.7 years, MACCE1 rate was not significantly lower group than non-escalation (9.8 14.3/1,000 person-years, respectively; hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.43-1.09; p=0.11). Kaplan-Meier curves showed similar results (log-rank risk death did differ groups. MACCE2 rate, which additionally includes coronary/peripheral revascularization, (24.5 35.4/1,000 HR, 0.70; CI, 0.52-0.94; p=0.017). hard ASCVD achieving statins. it had benefit reducing revascularization rates

Language: Английский

Ticagrelor is Associated with Increased Rosuvastatin Blood Concentrations in Patients who have had a Myocardial Infarction DOI